WO2002034773A3 - Streptococcal genes - Google Patents

Streptococcal genes Download PDF

Info

Publication number
WO2002034773A3
WO2002034773A3 PCT/GB2001/004749 GB0104749W WO0234773A3 WO 2002034773 A3 WO2002034773 A3 WO 2002034773A3 GB 0104749 W GB0104749 W GB 0104749W WO 0234773 A3 WO0234773 A3 WO 0234773A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
streptococcal genes
vaccines
peptides
streptococcal
Prior art date
Application number
PCT/GB2001/004749
Other languages
French (fr)
Other versions
WO2002034773A2 (en
Inventor
David William Holden
Jeremy Stuart Brown
Original Assignee
Imp College Innovations Ltd
David William Holden
Jeremy Stuart Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0026231A external-priority patent/GB0026231D0/en
Priority claimed from GB0028345A external-priority patent/GB0028345D0/en
Priority claimed from GB0102666A external-priority patent/GB0102666D0/en
Application filed by Imp College Innovations Ltd, David William Holden, Jeremy Stuart Brown filed Critical Imp College Innovations Ltd
Priority to US10/415,478 priority Critical patent/US20040116661A1/en
Priority to JP2002537762A priority patent/JP4183504B2/en
Priority to EP01976527A priority patent/EP1330473A2/en
Priority to AU2001295795A priority patent/AU2001295795A1/en
Priority to CA002426738A priority patent/CA2426738A1/en
Publication of WO2002034773A2 publication Critical patent/WO2002034773A2/en
Publication of WO2002034773A3 publication Critical patent/WO2002034773A3/en
Priority to US11/941,513 priority patent/US20090280141A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptides derived from S. pneumoniae are identified as virulence determinants and may be useful in the preparation of vaccines for the treatment of infection. The peptides may be used as antigens or in the preparation of attenuated microorganisms for use as live oral vaccines.
PCT/GB2001/004749 2000-10-26 2001-10-26 Streptococcal genes WO2002034773A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/415,478 US20040116661A1 (en) 2000-10-26 2001-10-26 Streptococcal genes
JP2002537762A JP4183504B2 (en) 2000-10-26 2001-10-26 Streptococcus gene
EP01976527A EP1330473A2 (en) 2000-10-26 2001-10-26 Streptococcal genes
AU2001295795A AU2001295795A1 (en) 2000-10-26 2001-10-26 Streptococcal genes
CA002426738A CA2426738A1 (en) 2000-10-26 2001-10-26 Streptococcal genes
US11/941,513 US20090280141A1 (en) 2000-10-26 2007-11-16 Streptococcal Genes

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0026231.1 2000-10-26
GB0026231A GB0026231D0 (en) 2000-10-26 2000-10-26 Streptococcal genes
GB0028345.7 2000-11-21
GB0028345A GB0028345D0 (en) 2000-11-21 2000-11-21 Streptococcal genes
GB0102666.5 2001-02-02
GB0102666A GB0102666D0 (en) 2001-02-02 2001-02-02 Streptococcal Genes
US28811801P 2001-05-02 2001-05-02
US60/288,118 2001-05-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/941,513 Continuation US20090280141A1 (en) 2000-10-26 2007-11-16 Streptococcal Genes

Publications (2)

Publication Number Publication Date
WO2002034773A2 WO2002034773A2 (en) 2002-05-02
WO2002034773A3 true WO2002034773A3 (en) 2003-03-13

Family

ID=27447899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004749 WO2002034773A2 (en) 2000-10-26 2001-10-26 Streptococcal genes

Country Status (4)

Country Link
EP (1) EP1330473A2 (en)
AU (1) AU2001295795A1 (en)
CA (1) CA2426738A1 (en)
WO (1) WO2002034773A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0208499D0 (en) * 2002-04-12 2002-05-22 Microscience Ltd Streptococcal genes
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
US8729013B2 (en) 2004-08-26 2014-05-20 The University Of Western Ontario Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
AU2010215065B2 (en) * 2009-02-20 2014-05-15 Australian Poultry Crc Pty Limited Live attenuated vaccines
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
CN102844047B (en) 2009-09-02 2017-04-05 诺华股份有限公司 Immunogenic composition containing TLR active regulators
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as tlr activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
EA031379B1 (en) 2010-03-23 2018-12-28 Новартис Аг Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
US11098349B2 (en) * 2015-11-04 2021-08-24 The Translational Genomics Research Institute Systems and methods of diagnosing and characterizing infections
EA202091931A1 (en) 2018-02-12 2020-11-05 Иниммьюн Корпорейшн Toll-Like Receptor Ligands
US11473093B2 (en) 2020-11-04 2022-10-18 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof
GB2600962A (en) * 2020-11-12 2022-05-18 Ucl Business Plc Live attenuated strain of Streptococcus pneumoniae and pharmaceutical compositions comprising a live attenuated strain of S. pneumoniae

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
WO1998006734A1 (en) * 1996-08-16 1998-02-19 Smithkline Beecham Corporation Novel prokaryotic polynucleotides, polypeptides and their uses
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
WO1998023631A1 (en) * 1996-11-27 1998-06-04 Smithkline Beecham Corporation Novel bacterial polypeptides and polynucleotides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
WO1998006734A1 (en) * 1996-08-16 1998-02-19 Smithkline Beecham Corporation Novel prokaryotic polynucleotides, polypeptides and their uses
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
WO1998023631A1 (en) * 1996-11-27 1998-06-04 Smithkline Beecham Corporation Novel bacterial polypeptides and polynucleotides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BROWN J S ET AL: "A STREPTOCOCCUS PNEUMONIAE PATHOGENICITY ISLAND ENCODING AN ABC TRANSPORTER INVOLVED IN IRON UPTAKE AND VIRULENCE", MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, VOL. 40, NR. 3, PAGE(S) 572-585, ISSN: 0950-382X, XP001057233 *
DATABASE EMBL 17 October 1998 (1998-10-17), XP002191216 *
DATABASE EMBL 3 February 1992 (1992-02-03), XP002191215 *
DATABASE EMBL 31 July 2001 (2001-07-31), XP002191217 *
DATABASE EMBL XP002198687 *
FONTAN P A ET AL: "B-437. A CHOLINE TRANSPORTER AS A VIRULENCE DETERMINANT OF STREPTOCOCCUS PNEUMONIAE", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, VOL. 97, NR. 97, PAGE(S) 103, ISSN: 0067-2777, XP000892162 *
SPELLERBERG B ET AL: "PYRUVATE OXIDASE, AS A DETERMINANT OF VIRULENCE IN STREPTOCOCCUS PNEUMONIAE", MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, VOL. 19, NR. 4, PAGE(S) 803-813, ISSN: 0950-382X, XP002070537 *

Also Published As

Publication number Publication date
WO2002034773A2 (en) 2002-05-02
EP1330473A2 (en) 2003-07-30
AU2001295795A1 (en) 2002-05-06
CA2426738A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
WO2002034773A3 (en) Streptococcal genes
BR0009166A (en) Vaccine
DK1187629T3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2006078318A3 (en) Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
ZA965482B (en) Novel antigen.
WO2003065973A8 (en) Multivalent streptococcal vaccine compositions and methods for use
WO2002075507A3 (en) Anti-bacterial vaccine compositions
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
DK1154791T3 (en) Neisseria Vaccine Compositions and Methods
AP1502A (en) Genes and proteins, and their uses.
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
EP2272532A3 (en) Rotavirus vaccine
EP1074266A3 (en) Live attenuated bacteria for use in a vaccine
MY127452A (en) Vaccines.
WO2000037490A3 (en) Outer surface proteins, their genes, and their use
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2001040472A3 (en) Streptococcus pneumoniae antigens
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
ATE297985T1 (en) ORAL VACCINES AGAINST YERSINIA PESTIS INFECTIONS
AP1679A (en) Outer surface proteins, their genes, and their use.
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis
DK1660121T3 (en) Live attenuated bacterial vaccine
WO2004003153A3 (en) Live replicating spumavirus vector
WO2000062803A3 (en) ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001976527

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2426738

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002537762

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001976527

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10415478

Country of ref document: US